公开(公告)号：US07829294B2

公开(公告)日：2010-11-09

申请号：US11722998

申请日：2005-12-27

申请人： Masanao Matsuo ,  Hiroyuki Ebinuma ,  Osamu Miyazaki ,  Kyoko Tanaka ,  Akiko Suzuki

发明人： Masanao Matsuo ,  Hiroyuki Ebinuma ,  Osamu Miyazaki ,  Kyoko Tanaka ,  Akiko Suzuki

IPC分类号： G01N33/543 ,  G01N33/573 ,  G01N33/577 ,  C07K16/36 ,  C12N5/20 ,  C12P21/08

CPC分类号： C07K16/18 ,  C07K14/745 ,  C07K14/75 ,  G01N33/86 ,  G01N2333/75 ,  G01N2800/224

摘要： The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an Aα-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.

摘要翻译： 本发明涉及针对可溶性纤维蛋白的单克隆抗体，其特异性识别通过纤维蛋白原凝血酶消化形成的可溶性纤维蛋白的Aα链的C末端区域中新发生的构象改变部位。 本发明还涉及产生抗体的杂交瘤，使用抗体的免疫测定方法，以及通过使用测定方法测量样品中的可溶性纤维蛋白水平来评估测试样品中的高凝状态的方法。 通过使用本发明的单克隆抗体，可以特异性检测仅反映初始高凝状态的纤维蛋白溶酶未起作用的可溶性纤维蛋白。

公开(公告)号：US20090215118A1

公开(公告)日：2009-08-27

申请号：US12397879

申请日：2009-03-04

申请人： Kimiyasu ISOBE ,  Seiki Yamaguchi ,  Masayuki Kobayashi ,  Shinya Kumagai ,  Takami Sarashina

发明人： Kimiyasu ISOBE ,  Seiki Yamaguchi ,  Masayuki Kobayashi ,  Shinya Kumagai ,  Takami Sarashina

IPC分类号： C12P21/00 ,  C12N9/48 ,  C07H21/00 ,  C12N15/74 ,  C12N1/21 ,  C12N1/20

CPC分类号： C12N9/80

摘要： A D-aminoacylase having a high substrate specificity is provided. This D-aminoacylase can produce D-amino acids from N-acetyl-D,L-amino acids conveniently and efficiently at a low cost.A D-aminoacylase produced by a microorganism of genus Defluvibacter; which acts on a N-acetyl-D-amino acid; which has a molecular weight (as determined by electrophoresis) of about 55,000 daltons, and an isoelectric point (as determined by two-dimensional electrophoresis for denatured system) of 5.3; which acts on N-acetyl-D-valine, N-acetyl-D-leucine, and the like, but not on N-acetyl-L-valine, N-acetyl-L-leucine, and the like; which has an optimal temperature of 37° C. (pH 8) and an optimal pH value of 8 to 8.5 at 37° C.; and whose activity is inhibited by Mn2+, Co2+, Ni2+, and Zn2+ each at 1 mmol/L, and by dithiothreitol, 2-mercaptoethanol, o-phenanthroline, and L-cysteine each at 5 mmol/L.

摘要翻译： 提供了具有高底物特异性的D-氨基酸酰化酶。 该D-氨基酸酶可以以低成本方便且有效地从N-乙酰基-D，L-氨基酸产生D-氨基酸。 由去纤维杆菌属的微生物产生的D-氨基酸酰化酶; 其作用于N-乙酰基-D-氨基酸; 其具有约55,000道尔顿的分子量（通过电泳测定）和5.3的等电点（通过用于变性体系的二维电泳测定）; 其作用于N-乙酰基-D-缬氨酸，N-乙酰基-D-亮氨酸等，但不适用于N-乙酰基-L-缬氨酸，N-乙酰基-L-亮氨酸等; 其最适温度为37℃（pH8），最适pH值为8〜8.5，在37℃下。 Mn2 +，Co2 +，Ni2 +和Zn2 +各自以1 mmol / L的速度抑制其活性，二硫苏糖醇，2-巯基乙醇，邻菲咯啉和L-半胱氨酸各自以5 mmol / L的速度进行抑制。

公开(公告)号：US20080166746A1

公开(公告)日：2008-07-10

申请号：US12047357

申请日：2008-03-13

申请人： Mitsuaki Yamamoto ,  Shoko Yamamoto ,  Mitsuhiro Nakamura ,  Kazunori Saito

发明人： Mitsuaki Yamamoto ,  Shoko Yamamoto ,  Mitsuhiro Nakamura ,  Kazunori Saito

IPC分类号： C12Q1/60 ,  C12Q1/00

CPC分类号： G01N33/92 ,  C07F7/18 ,  C12Q1/44 ,  C12Q1/60 ,  C12Q1/61 ,  G01N2800/044

摘要： A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.

摘要翻译： 一种脂质测定方法，其特征在于在有机硅化合物存在下测定血液成分中所含的脂质。 该方法可以满足直接方法的特定条件，同时满足对测定精度无影响，测定仪器无负担，易于获得的要求。

公开(公告)号：US20070154976A1

公开(公告)日：2007-07-05

申请号：US10579765

申请日：2004-11-18

申请人： Yuriko Taniguchi ,  Kazunori Saito

发明人： Yuriko Taniguchi ,  Kazunori Saito

IPC分类号： C12Q1/26 ,  C12Q1/30

CPC分类号： G01N33/723 ,  C12Q1/26 ,  C12Q1/28 ,  G01N33/6812 ,  G01N33/6842 ,  G01N33/721 ,  G01N33/725

摘要： The present invention provides a convenient, efficient method for determining a substrate contained in a hemoglobin-containing sample and a reagent therefor, which can be employed for a variety of automatic analyzers while reducing interference of hemoglobin contained in the sample. A method for determining a substrate contained in a hemoglobin-containing sample through reaction of an oxidase with the substrate and optical measurement of the produced hydrogen peroxide by use of a peroxidase and an oxidizable color producing reagent, characterized in that the hemoglobin-containing sample is treated with an anionic surfactant selected from among a polyoxyethylene alkyl ether sulfate salt, a polyoxyethylene alkylphenyl ether sulfate salt, a polyoxyethylene alkyl ether phosphate, a polyoxyethylene alkyl sulfosuccinate, a polyoxyethylene alkyl ether carboxylate salt, a polyoxyethylene alkyl ether sulfonate salt, triethanolamine lauryl sulfate, an alkyl sulfosuccinate, and an alkylphenyl ether sulfonate salt.

摘要翻译： 本发明提供了一种用于测定含有血红蛋白的样品及其试剂中含有的底物的方便，有效的方法，其可以用于各种自动分析仪，同时减少样品中所含的血红蛋白的干扰。 一种通过使氧化酶与底物反应来测定含有血红蛋白的样品中含有的底物的方法，通过使用过氧化物酶和可氧化颜色产生试剂对产生的过氧化氢进行光学测定，其特征在于，含有血红蛋白的样品为 用聚氧乙烯烷基醚硫酸盐，聚氧乙烯烷基苯基醚硫酸盐，聚氧乙烯烷基醚磷酸盐，聚氧乙烯烷基磺基琥珀酸盐，聚氧乙烯烷基醚羧酸盐，聚氧乙烯烷基醚磺酸盐，月桂基硫酸三乙醇胺， ，烷基磺基琥珀酸烷基酯和烷基苯基醚磺酸盐。

公开(公告)号：US20070154879A1

公开(公告)日：2007-07-05

申请号：US11684827

申请日：2007-03-12

申请人： Hiroyuki Ebinuma ,  Kumiko Yuki

发明人： Hiroyuki Ebinuma ,  Kumiko Yuki

IPC分类号： C12Q1/00 ,  C12Q1/26

CPC分类号： C12Q1/32

摘要： A method for quantitatively determining a specific component in a biological specimen, which includes reacting a biological specimen, in the presence of an electron acceptor, with an enzyme which has an ability, by the dehydrogenation reaction, to oxidize the specific component or a substance derived from the specific component, and measuring the formed reductant of the electron acceptor, wherein the method avoids the influence of hemoglobin effectively if any contained in the specimen by using a measuring reagent containing albumin, thereby making an quantitative determination of the target component accurately; and a reagent for the quantitative determination.

摘要翻译： 一种用于定量测定生物样本中的特定成分的方法，其包括使生物样品在电子受体存在下与通过脱氢反应具有能够氧化特定成分或衍生物质的酶反应的酶 测定形成的电子受体的还原剂，其中，通过使用含有白蛋白的测定试剂，如果含有试样中的任何含量，则可有效地避免血红蛋白的影响，从而准确地定量确定目标成分; 和用于定量测定的试剂。

公开(公告)号：US20070117211A1

公开(公告)日：2007-05-24

申请号：US11429447

申请日：2006-05-08

申请人： Tetsuo Nagano ,  Hirotatsu Kojima

发明人： Tetsuo Nagano ,  Hirotatsu Kojima

IPC分类号： G01N33/00 ,  C07D311/88

CPC分类号： C07D493/10 ,  Y10T436/177692

摘要： A compound represented by the following formula (I): wherein R1 and R2 represent amino groups that substitute at adjacent positions on the phenyl ring, provided that either of R1 and R2 represents a mono(C1-6 alkyl)-substituted amino group and the other represents an unsubstituted amino group; and R3 and R4 independently represent hydrogen atom or an acyl group, and an agent for measurement of nitrogen monoxide which comprises said compound.

摘要翻译： 由下式（I）表示的化合物：其中R 1和R 2代表在苯环的相邻位置取代的氨基，条件是R 1， SUP> 1和R 2表示单（C 1-6烷基）取代的氨基，另一个表示未取代的氨基; R 3和R 4独立地表示氢原子或酰基，和含有所述化合物的一氧化氮测定剂。

公开(公告)号：US20070082357A1

公开(公告)日：2007-04-12

申请号：US11543055

申请日：2006-10-05

申请人： Yoshinori Hasegawa ,  Yu-uichi Ando ,  Kaoru Shimokata

发明人： Yoshinori Hasegawa ,  Yu-uichi Ando ,  Kaoru Shimokata

IPC分类号： C12Q1/68

CPC分类号： C12N9/1051 ,  C12Q1/6876 ,  C12Q2600/156

摘要： A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan; and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction, thereby reducing the adverse drug reaction cased by the administration of irinotecan.

摘要翻译： 评估由伊立替康的给药引起的不良药物反应的风险的估计方法; 以及减少由伊立替康给药引起的药物不良反应的方法。 基于外显子1的单核苷酸多态性，基于UGT1基因的启动子区域的TA重复序列的重复数和两种类型的多态性（211-和686位的碱基）的差异的多态性 被分析。 根据分析资料，估计伊立替康的施用引起药物不良反应的风险。 此外，根据不良药物反应的表达风险，为个体患者设计伊立替康的给药剂量，从而减少由伊立替康给药引起的药物不良反应。

公开(公告)号：US07198905B2

公开(公告)日：2007-04-03

申请号：US10471823

申请日：2002-03-01

申请人： Hiroyuki Ebinuma ,  Kazunori Saito ,  Hirohito Sone ,  Nobuhiro Yamada

发明人： Hiroyuki Ebinuma ,  Kazunori Saito ,  Hirohito Sone ,  Nobuhiro Yamada

IPC分类号： C12Q1/32

CPC分类号： G01N33/66

摘要： The present invention provides a screening method by which a prediabetic state can be more accurately determined and many test samples can be treated without physical burden on patients, and a diagnostic reagent used for it. By measuring a D-mannose concentration, preferably a D-mannose concentration and a glucose concentration, in a body fluid collected from a subject, and comparing them with their respective standard values, a patient in a prediabetic state can be detected. Further, the measurement of the mannose concentration is conducted by allowing an enzyme having an oxidizing activity on mannose by dehydrogenation to react on the mannose in a sample in the presence of an electron acceptor, and quantitatively determining the formed reductant of the electron acceptor.

摘要翻译： 本发明提供了一种筛选方法，通过该方法能够更准确地确定前列腺状态，并且可以对患者进行治疗而不会对身体造成负担的许多测试样品以及用于其的诊断试剂。 通过在从受试者收集的体液中测量D-甘露糖浓度，优选D-甘露糖浓度和葡萄糖浓度，并将其与它们各自的标准值进行比较，可以检测患有糖尿病状态的患者。 此外，甘露糖浓度的测定是通过在电子受体的存在下，使通过脱氢使对甘露糖具有氧化活性的酶在样品中与甘露糖反应，并定量测定形成的电子受体的还原剂来进行的。

公开(公告)号：US20070015141A1

公开(公告)日：2007-01-18

申请号：US11483883

申请日：2006-07-10

申请人： Sachiko Ito ,  Michiko Kawamoto ,  Kiichiro Kobori ,  Koji Ushizawa

发明人： Sachiko Ito ,  Michiko Kawamoto ,  Kiichiro Kobori ,  Koji Ushizawa

IPC分类号： C12Q1/70 ,  G01N33/553

CPC分类号： G01N15/0205 ,  G01N33/585

摘要： A method for accurately determining the particle diameter of gold colloid in a simple manner, and a gold colloid solution with a particle diameter within a desired range are described. A method for estimating the particle diameter distribution width of gold colloid based on the measurement of, in addition to the maximum absorption wavelength, a ratio (AλX/Aλmax) of the absorbance (AλX) at a wavelength differing from the maximum absorption wavelength to the absorbance (Aλmax) at the maximum absorption wavelength of the gold colloid solution, and the gold colloid solution obtained by the method are provided.

摘要翻译： 描述了以简单的方式精确测定金胶体的粒径的方法和粒径在期望范围内的金胶体溶液。 基于除了最大吸收波长之外的测量，用于估计金胶体的粒径分布宽度的方法，其比例（λmax / 在金胶体溶液的最大吸收波长处，与最大吸收波长不同于吸光度（λmax max）的波长处的吸光度（Al x X S）和金 提供了通过该方法获得的胶体溶液。

公开(公告)号：US07087766B2

公开(公告)日：2006-08-08

申请号：US10204417

申请日：2001-02-28

申请人： Tetsuo Nagano ,  Yasuteru Urano ,  Ken-ichi Setsukinai

发明人： Tetsuo Nagano ,  Yasuteru Urano ,  Ken-ichi Setsukinai

IPC分类号： C07D311/02 ,  C07D311/78

CPC分类号： C07D311/16 ,  G01N31/225

摘要： A compound represented by general formula (I) or (II) or a salt thereof and an agent for measurement of a reactive oxygen comprising said compound or a salt thereof: wherein R1 and R2 independently represent an aryl group which may be substituted, e.g., a phenyl group substituted with an amino group or a hydroxy group, and R3 represents a 2-carboxyphenyl group which may be substituted.

摘要翻译： 由通式（I）或（II）表示的化合物或其盐和包含所述化合物或其盐的活性氧测量剂：其中R 1和R 2 独立地表示可以被取代的芳基，例如被氨基或羟基取代的苯基，R 3表示可以被取代的2-羧基苯基。